Ebola virus RNA-dependent RNA polymerase (L (occasionally L protein or EBOV L))

Ebola virus RNA-dependent RNA polymerase (L protein) is a large multifunctional viral enzyme essential for the replication and transcription of the Ebola virus genome. It acts in complex with the viral cofactor VP35 and, together with VP30 and viral nucleoprotein (NP), comprises the ribonucleoprotein (RNP) complex responsible for synthesizing viral RNA within infected cells[1][3][4][5]. The L protein contains filovirus-specific structural elements required for RNA synthesis, and its interaction with VP35 is crucial for its enzymatic activity as well as for evasion of host immune responses. Because of its essential and highly conserved role in the Ebola virus life cycle, the polymerase is regarded as a promising target for broad-spectrum antiviral drug development. Suramin is a known inhibitor of the polymerase activity in vitro, but no approved small-molecule drugs specifically targeting the Ebola virus polymerase are available for clinical use. Attempts to target the enzyme directly (e.g., with remdesivir) have met limited clinical success, highlighting the challenges of antiviral drug development against this target[1][2][3][9].

Other names

Ebola virus L proteinEbola virus polymerase complexEBOV LRNA polymerase LL–VP35 complex (when referring to the active holoenzyme)Filovirus L protein

Suramin: inhibits by binding to the NTP entry channel, blocking substrate access to the catalytic site[1][3] Remdesivir: acts as a nucleotide analog intended to be incorporated by the polymerase, blocking elongation[9]